BUZZ-Hims & Hers shines bright in a testing year for telehealth stocks

** Shares of Hims & Hers Health HIMS.N more than double, while other telehealth firms are set to end the year in declines

** HIMS' shares set for their second straight year of gains helped by co's offering of compounded versions of GLP-1 weight-loss drugs such as Novo Nordisk's NOVOb.CO Wegovy

** HIMS, Mangoceuticals MGRX.0, WeightWatchers WW.O and Teladoc Health TDOC.N offer compounded and branded versions of GLP-1 weight-loss drugs on their platforms

** Soaring demand for weight-loss drugs made by Eli Lilly LLY.N and Novo Nordisk have pushed patients to cheaper compounded versions

** Shares of telehealth firms have been volatile this year on "headlines tied to the overall supply availability of all things GLP-1-related," brokerage Leerink Partners says

** Shares of TDOC and LFMD were also hit after Amazon AMZN.O announced low-cost telehealth services for Prime members; shares of LFMD fell to nearly four-month low

** Shares of HIMS have more than doubled YTD

** Shares of TDOC set for fourth straight year of decline, LFMD down 38.2% vs a ~327% gain in 2023; MGRX down 41% and WW down 85.5% vs a 126.7% gain in 2023

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))